What was AbbVie's revenue in Q1 2026?

AbbVie reported revenue of $14.5 billion in Q1 2026, beating estimates of $14.1 billion.

Why did AbbVie stock rise 5%?

The stock rose after the company reported Q1 results that beat estimates and raised its full-year revenue guidance, driven by strong sales of Skyrizi and Rinvoq.

What is AbbVie's guidance for 2026?

AbbVie raised its full-year revenue guidance to $58-59 billion and adjusted EPS guidance to $12.50-$12.80.

How did Skyrizi and Rinvoq sales impact AbbVie's results?

Skyrizi sales grew 25% to $4.5 billion and Rinvoq sales grew 30% to $2.8 billion, significantly contributing to the earnings beat.

Does Waraqati recommend buying AbbVie stock?

No, Waraqati does not provide buy or sell recommendations. We offer neutral analysis of financial results only.

AbbVie Stock Jumps 5% on Q1 Beat, Raised 2026 Guidance

AbbVie (ABBV) shares jumped 5% after reporting Q1 2026 results that topped analyst expectations, with revenue of $14.5B and EPS of $3.20. The company also raised its full-year revenue guidance, citing strong performance from key drugs Skyrizi and Rinvoq.

Shares of AbbVie (ABBV) rose 5% in after-hours trading following the release of its Q1 2026 earnings, which surpassed consensus estimates. The pharmaceutical giant reported revenue of $14.5 billion, beating the $14.1 billion forecast, and earnings per share (EPS) of $3.20, above the expected $3.05.

Key Financial Results

Metric	Q1 2026	Estimates	YoY Change
Revenue	$14.5B	$14.1B	+12%
Net Income	$4.2B	-	+15%
EPS	$3.20	$3.05	+14%

Highlights from the Report

AbbVie attributed the strong performance to robust sales of its immunology drugs Skyrizi (for psoriasis) and Rinvoq (for rheumatoid arthritis). Skyrizi sales surged 25% year-over-year to $4.5 billion, while Rinvoq grew 30% to $2.8 billion. Oncology and neuroscience products also contributed to revenue growth.

Guidance Update

The company raised its full-year 2026 revenue guidance to a range of $58-59 billion, up from the previous $56-57 billion. Adjusted EPS guidance was also lifted to $12.50-$12.80.

Stock Impact

ABBV shares jumped 5% in after-hours trading, reflecting investor optimism over the earnings beat and raised guidance. The stock had been relatively stable in recent months.

What This Means for Investors

The strong results demonstrate AbbVie's ability to offset declining Humira sales (due to biosimilar competition) with growth from its newer drugs. The raised guidance signals management's confidence in sustaining momentum. However, investors should monitor competitive pressures in the pharmaceutical market.